Exact Sciences' Earnings Hammer Short-Sellers (Again)

Americans have historically done poorly when it comes to sticking to recommended guidelines for colon cancer screening, but a new test launched by Exact Sciences (NASDAQ: EXAS) may be changing that -- and frustrating short-sellers in the process.

Bears have been lining up against Exact Sciences since Cologuard's launch, arguing that the test isn't nearly as useful as a colonoscopy and that doctors and patients will shun it. So far, that hasn't been the case, and as a result, short-sellers have been forced to cover their position in Exact Sciences, pushing shares higher.

Image source: Getty Images.

Source: Fool.com